Background：Namilumab alternative identifier MT203 is a human monoclonal antibody class IgG1 kappa that targets granulocyte macrophage-colony stimulating factor GM-CSF, which is also known as colony stimulating factor 2 CSF2. Namilumab was produced by Micromet Inc and is under development by Takeda Pharmaceuticals International. It is currently being researched for application in rheumatoid arthritis RA and psoriatic arthritis. Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis and rheumatoid arthritis.
